International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)

Precision Cancer Medicine in the Era of Artificial Intelligence

Dr. Swati Joshi[1], Dr. Prakash Menon[2], Mrs. Neelam Sinha[3], Dr. Chetan Kulkarni[4], Mr. Himanshu Das[5]

[1]Professor Department of Pharmaceutics, National Institute of Drug Sciences, Indore, India swatijoshi64@gmail.com
[2]Associate Professor Department of Pharmaceutical Biotechnology, National Institute of Drug Sciences, Indore, India prakash.menon85@gmail.com
[3]Assistant Professor Department of Pharmacy Practice, National Institute of Drug Sciences, Indore, India neelamsinha04@gmail.com
[4]Professor Department of Pharmacology, National Institute of Drug Sciences, Indore, India chetan.kulkarni9@gmail.com
[5]Associate Professor Department of Pharmaceutical Analysis, National Institute of Drug Sciences, Indore, India himanshudas83@gmail.com

ABSTRACT

Precision cancer medicine has entered a new era driven by rapid advances in artificial intelligence (AI), computational biology, and high-throughput molecular technologies. While traditional precision oncology primarily relied on genomic profiling to guide targeted therapies, contemporary cancer care increasingly integrates multidimensional biomedical information—including radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, liquid biopsy, electronic health records, and real-world clinical data—to provide individualized diagnosis and treatment. Artificial intelligence has emerged as the central enabling technology capable of interpreting these complex datasets through machine learning, deep learning, computer vision, natural language processing, graph neural networks, multimodal learning, and foundation models. AI-powered systems are transforming every stage of cancer management by improving early diagnosis, prognostic prediction, biomarker discovery, treatment selection, immunotherapy response assessment, adaptive radiation planning, surgical decision-making, drug discovery, and survivorship care. Emerging innovations including generative AI, digital twins, federated learning, explainable AI, single-cell sequencing, spatial biology, and cloud-based intelligent healthcare systems further expand the scope of personalized oncology. Despite these remarkable advances, important scientific, ethical, technical, and regulatory challenges remain regarding data quality, interoperability, algorithmic bias, cybersecurity, transparency, validation, and equitable clinical implementation. This review provides a comprehensive overview of precision cancer medicine in the era of artificial intelligence, highlighting technological foundations, current clinical applications, emerging innovations, and future perspectives that are reshaping modern oncology.[1]

Keywords: *Precision cancer medicine, Artificial intelligence, Precision oncology, Machine learning, Deep learning, Digital pathology, Multi-omics, Clinical decision support, Radiomics, Personalized medicine.*

Article Info
Received: 05 December 2025, received in revised form: 15 December 2025, accepted: 20 December 2025, available online: 30 December 2025; Volume: 1; Issue: 5; Pages: 15-21.

Citation: Joshi, S., 2025. Precision Cancer Medicine in the Era of Artificial Intelligence. *International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)* 1(5): 15-21.
DOI:

Introduction

Cancer remains one of the most complex human diseases, characterized by remarkable biological heterogeneity arising from genetic mutations, epigenetic alterations, dysregulated gene expression, metabolic reprogramming, immune interactions, and continuous evolution within the tumor microenvironment. Although major advances in molecular diagnostics and targeted therapeutics have significantly improved outcomes for many malignancies, patients with similar clinicopathological diagnoses frequently demonstrate markedly different therapeutic responses, recurrence patterns, and survival outcomes. These observations emphasize the limitations of conventional treatment strategies based solely on population-level evidence and highlight the growing importance of individualized precision medicine.[2]

The rapid expansion of biomedical technologies has generated enormous volumes of patient-specific information through medical imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, liquid biopsy, laboratory investigations, wearable health technologies, and electronic health records. Together, these diverse datasets provide an increasingly comprehensive understanding of cancer biology; however, their complexity often exceeds the analytical capabilities of traditional statistical approaches and routine clinical workflows.[3]

Artificial intelligence has emerged as one of the most transformative technologies in modern oncology by enabling automated analysis of multidimensional biomedical data. AI algorithms identify complex biological relationships, recognize hidden disease patterns, generate individualized prognostic predictions, estimate therapeutic response, and support evidence-based clinical decision-making. Rather than replacing clinicians, AI functions as an intelligent clinical partner that augments physician expertise while improving efficiency, consistency, and diagnostic precision.[4]
The integration of artificial intelligence with precision cancer medicine is redefining the future of oncology by enabling predictive, preventive, adaptive, and highly personalized approaches to cancer diagnosis, treatment, and long-term patient management.[5]

2. Evolution of Precision Cancer Medicine

The concept of precision cancer medicine has evolved considerably over recent decades. Early oncology relied primarily on histopathological classification, anatomical staging, and standardized therapeutic protocols that treated patients with similar diagnoses using comparable treatment strategies. Although these approaches remain clinically important, they frequently failed to account for the substantial biological diversity observed among individual tumors.[6]
The introduction of next-generation sequencing transformed cancer care by enabling comprehensive genomic characterization of tumors. Identification of actionable alterations in genes such as EGFR, ALK, BRAF, KRAS, PIK3CA, and HER2 facilitated the development of targeted therapies that substantially improved outcomes for selected patient populations.[7]
Subsequent research demonstrated that genomic alterations alone could not fully explain treatment response, tumor evolution, metastatic progression, or therapeutic resistance. Consequently, precision oncology expanded beyond genomics to include transcriptomics, proteomics, metabolomics, epigenomics, immunomics, radiomics, and digital pathology.
At the same time, rapid advances in artificial intelligence enabled integration of these heterogeneous biomedical datasets into comprehensive computational models capable of supporting increasingly individualized clinical decision-making. Precision cancer medicine has therefore evolved from molecular profiling toward intelligent systems biology supported by advanced computational technologies.[8]
Today, precision oncology represents an integrated multidisciplinary framework that combines molecular biology, computational medicine, and clinical expertise to optimize patient-centered cancer care.[9]

3. Artificial Intelligence as the Foundation of Precision Oncology

Artificial intelligence has become the computational foundation of modern precision cancer medicine because of its ability to analyze complex, high-dimensional biomedical datasets that exceed human analytical capacity.[10]
Machine learning algorithms identify nonlinear relationships among clinical characteristics, molecular alterations, laboratory biomarkers, imaging findings, pathological features, and treatment outcomes. Deep learning automatically extracts hierarchical representations from medical images and digital pathology slides without requiring manually engineered features.
Transformer architectures efficiently process multimodal clinical information including imaging, pathology reports, genomic sequencing, laboratory data, and electronic health records. Graph neural networks model biological interaction networks involving genes, proteins, signaling pathways, and metabolic processes, while foundation models learn generalized biomedical representations that can be adapted across numerous oncology applications.
Together, these computational approaches support individualized diagnosis, prognostic prediction, therapeutic optimization, toxicity estimation, and clinical decision support throughout the cancer care continuum.[11]

4. Multi-Omics Integration Beyond Genomics

Although genomic sequencing remains central to precision medicine, cancer biology extends far beyond DNA mutations alone. Modern precision oncology increasingly incorporates multiple complementary molecular layers including epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiomics, and immunomics to achieve comprehensive biological characterization of tumors.[12]
Epigenomic analysis examines DNA methylation and chromatin remodeling that regulate gene expression without altering nucleotide sequences. Transcriptomics evaluates dynamic messenger RNA expression patterns, while proteomics measures functional protein abundance and signaling activity. Metabolomics characterizes downstream metabolic pathways associated with tumor growth, whereas immunomics investigates immune-cell composition and inflammatory signaling within the tumor microenvironment.
Artificial intelligence integrates these diverse omics datasets into unified computational models capable of improving biomarker discovery, molecular classification, prognostic prediction, and personalized therapeutic selection. Such multidimensional analyses provide more comprehensive understanding of tumor biology than genomics alone.[13]

5. Artificial Intelligence in Cancer Diagnosis

Early and accurate diagnosis remains one of the most important determinants of successful cancer treatment. Artificial intelligence has significantly improved diagnostic precision through automated interpretation of radiological imaging, digital pathology, molecular diagnostics, and laboratory investigations.[14]

Deep learning algorithms accurately detect malignant lesions, classify tumor subtypes, segment anatomical structures, estimate disease stage, and identify metastatic disease across computed tomography, magnetic resonance imaging, positron emission tomography, mammography, ultrasound, endoscopy, and digital pathology.

Computer vision systems also improve consistency by reducing interobserver variability among clinicians while providing rapid second-opinion analysis. Continuous learning from expanding clinical datasets enables these models to improve progressively, supporting increasingly accurate diagnosis across diverse healthcare environments.[15]

6. Radiomics, Digital Pathology, and Computational Imaging

Medical imaging and digital pathology form essential pillars of precision cancer medicine. Radiomics extracts quantitative imaging biomarkers describing tumor morphology, vascularity, texture, shape, and spatial heterogeneity from routine clinical imaging studies.[16]

Digital pathology enables whole-slide imaging and artificial intelligence-assisted analysis of millions of microscopic tissue regions simultaneously. Deep learning models classify tumor subtypes, estimate histological grade, quantify immune infiltration, evaluate stromal remodeling, and predict clinically relevant molecular biomarkers directly from histopathological images.

The integration of radiological imaging with computational pathology provides complementary anatomical and microscopic information that substantially improves diagnostic accuracy and therapeutic planning while supporting increasingly individualized patient management.[17]

7. Genomic Medicine and Biomarker Discovery

Genomic medicine remains one of the cornerstones of precision oncology because identification of actionable genetic alterations enables targeted therapeutic interventions. Artificial intelligence enhances genomic analysis by prioritizing clinically relevant variants, predicting functional consequences of mutations, estimating treatment sensitivity, and identifying mechanisms of acquired drug resistance.[18]

Machine learning integrates genomic information with transcriptomics, proteomics, radiomics, pathology, and clinical outcomes to discover robust biomarker signatures associated with prognosis, recurrence, treatment response, and survival. These multidimensional biomarkers frequently outperform individual genomic alterations by providing more comprehensive representations of tumor biology.

As genomic databases continue to expand globally, AI-assisted biomarker discovery is expected to accelerate development of increasingly precise molecular diagnostics and individualized therapeutic strategies.[19]

8. Precision Immuno-Oncology

Immunotherapy has revolutionized cancer treatment by enabling the immune system to recognize and eliminate malignant cells. However, predicting immunotherapy response remains one of the most challenging aspects of precision oncology.

Artificial intelligence integrates genomic mutations, tumor mutational burden, PD-L1 expression, digital pathology, immune-cell composition, radiological imaging, transcriptomic profiles, and clinical variables to estimate individualized immunotherapy responsiveness.[20]

Deep learning algorithms characterize tumor-infiltrating lymphocytes, immune checkpoint expression, cytokine signaling pathways, and spatial organization of immune cells within the tumor microenvironment. These analyses improve patient selection while supporting optimization of immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, and emerging combination immunotherapies.

AI-driven immuno-oncology is expected to play an increasingly important role in expanding personalized cancer immunotherapy across diverse malignancies.[21]

9. Intelligent Clinical Decision Support

Modern oncology requires interpretation of enormous quantities of clinical information generated throughout diagnosis, treatment, and long-term follow-up. Artificial intelligence-powered clinical decision-support systems integrate radiological imaging, digital pathology, laboratory investigations, genomic sequencing, medication history, electronic health records, and patient-reported outcomes into unified clinical platforms.[22]

These intelligent systems generate individualized diagnostic assessments, prognostic predictions, treatment recommendations, toxicity estimates, and survivorship care plans through continuous analysis of multidimensional biomedical information. Interactive clinical dashboards facilitate multidisciplinary collaboration by presenting AI-generated insights in clinically interpretable formats that support evidence-based decision-making and personalized cancer care.

10. Artificial Intelligence in Personalized Cancer Therapy

Artificial intelligence has become an essential component of personalized cancer therapy by enabling comprehensive analysis of clinical, molecular, pathological, and imaging information to guide individualized treatment decisions. Unlike conventional therapeutic approaches that rely primarily on standardized clinical guidelines, AI integrates patient-specific characteristics to predict therapeutic efficacy, disease progression, and treatment-related toxicity.[23]

Machine learning algorithms estimate response to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, and multimodal treatment combinations using multidimensional clinical datasets. These predictive models assist oncologists in selecting therapies that maximize clinical benefit while minimizing unnecessary adverse effects and improving overall quality of life.

Rather than functioning as an autonomous decision-maker, AI serves as an intelligent clinical assistant that complements physician expertise and strengthens multidisciplinary cancer care.

11. Artificial Intelligence in Radiation Oncology and Surgical Oncology

Radiation oncology has experienced substantial advances through artificial intelligence–driven automation of tumor contouring, organ-at-risk segmentation, treatment planning, dose optimization, adaptive radiotherapy, and quality assurance.[24]

Deep learning algorithms rapidly analyze sequential imaging acquired during treatment, allowing individualized radiation plans to be continuously modified according to anatomical changes, tumor shrinkage, and biological response. These adaptive approaches improve tumor control while reducing unnecessary radiation exposure to surrounding healthy tissues.

Artificial intelligence also supports surgical oncology through three-dimensional reconstruction of patient anatomy, prediction of surgical margins, operative planning, robotic navigation, intraoperative image guidance, and estimation of postoperative outcomes. These technologies enhance surgical precision while reducing complications and improving functional recovery.

12. Drug Discovery, Digital Twins, and Computational Therapeutics

Emerging computational technologies are transforming oncology drug development through integration of artificial intelligence, systems biology, pharmacogenomics, and computational modeling. Machine learning algorithms identify therapeutic targets by analyzing genomic alterations, signaling pathways, protein interactions, and molecular networks associated with tumor progression.[25]

Generative artificial intelligence accelerates pharmaceutical research by designing novel drug molecules, predicting drug-target interactions, estimating toxicity profiles, and optimizing candidate compounds before laboratory validation.

Digital twins are also emerging as powerful computational tools capable of simulating disease progression and therapeutic response using patient-specific clinical, molecular, imaging, and physiological data. These virtual patient models may facilitate treatment optimization, individualized dosing strategies, and virtual clinical trials that accelerate development of innovative cancer therapies.

13. Explainable Artificial Intelligence and Responsible Implementation

As artificial intelligence becomes increasingly integrated into clinical oncology, transparency and interpretability have become essential requirements for safe implementation. Explainable artificial intelligence (XAI) enables clinicians to understand the reasoning underlying computational predictions, thereby improving confidence in AI-assisted decision-making.[26]

Visualization techniques including saliency maps, attention heatmaps, SHAP (Shapley Additive Explanations), Local Interpretable Model-Agnostic Explanations (LIME), and counterfactual analyses identify the clinical variables that contribute most strongly to individual predictions.

Responsible implementation further requires careful attention to algorithmic fairness, patient privacy, cybersecurity, informed consent, regulatory compliance, and continuous model validation. Transparent AI systems are expected to improve clinician acceptance while supporting ethical integration into routine oncology practice.

14. Digital Health, Wearable Technologies, and Remote Monitoring

The rapid expansion of digital health technologies has extended precision cancer medicine beyond hospital settings into continuous patient monitoring. Wearable devices now collect real-time physiological information including heart rate, physical activity, respiratory parameters, sleep quality, temperature, and oxygen saturation.[27]

Artificial intelligence analyzes these longitudinal data streams together with laboratory investigations, imaging findings, treatment records, and patient-reported outcomes to identify early signs of treatment toxicity, disease progression, functional decline, or recurrence.

Mobile health applications and remote monitoring platforms further facilitate personalized survivorship care by enabling continuous communication between patients and healthcare providers. These technologies support earlier clinical intervention while improving healthcare accessibility and patient engagement.

15. Challenges and Future Opportunities

Despite remarkable technological progress, precision cancer medicine continues to face several scientific, technical, ethical, and organizational challenges. High-dimensional biomedical datasets require standardized acquisition protocols, robust computational infrastructure, interoperable healthcare systems, and rigorous quality control procedures to ensure reliable clinical implementation.[28]

Algorithmic bias resulting from underrepresented patient populations may reduce predictive performance and contribute to healthcare disparities. Additional concerns include explainability of increasingly complex AI models, cybersecurity, data governance, reimbursement policies, regulatory approval, medico-legal responsibility, and equitable global access to advanced precision oncology technologies.

Addressing these challenges will require international collaboration, standardized validation methodologies, prospective multicenter clinical studies, transparent regulatory frameworks, and continuous clinician education to ensure responsible adoption.

16. Future Perspectives

The future of precision cancer medicine will be driven by increasingly intelligent healthcare ecosystems that integrate multi-omics technologies, digital pathology, radiomics, liquid biopsy, spatial biology, wearable biosensors, electronic health records, and real-world clinical data into continuously learning computational platforms.[29]

Foundation models trained on massive biomedical datasets are expected to provide generalized reasoning across multiple oncology disciplines, while generative AI will accelerate biomarker discovery, molecular design, scientific literature synthesis, and clinical documentation. Emerging technologies including quantum computing, federated learning, edge AI, robotic surgery, and autonomous laboratory systems may further enhance computational efficiency and clinical scalability.

These advances will progressively shift oncology toward predictive, preventive, adaptive, and highly personalized medicine capable of continuously learning from every patient encounter.

17. Discussion

Precision cancer medicine in the era of artificial intelligence represents a fundamental transformation in the diagnosis and treatment of malignant disease. By integrating radiology, pathology, genomics, transcriptomics, proteomics, metabolomics, immunology, digital health, and clinical information, AI provides comprehensive systems-level understanding of tumor biology that supports highly individualized patient management.

Applications spanning cancer diagnosis, biomarker discovery, prognostic prediction, immunotherapy optimization, adaptive radiation therapy, surgical planning, drug discovery, digital twins, and intelligent clinical decision support demonstrate the extraordinary potential of computational medicine to improve patient outcomes. Nevertheless, widespread clinical implementation requires continued multidisciplinary collaboration, transparent governance, robust validation, and responsible ethical oversight to ensure safe and equitable deployment across healthcare systems.[30]

18. Conclusion

Artificial intelligence is redefining precision cancer medicine by enabling comprehensive integration of molecular biology, medical imaging, digital pathology, clinical records, and emerging biomedical technologies into personalized clinical decision-making. Rather than relying on isolated biomarkers or conventional treatment paradigms, modern precision oncology increasingly embraces multidimensional computational approaches capable of capturing the full biological complexity of cancer.

Continued advances in multimodal learning, foundation models, digital twins, spatial biology, liquid biopsy, wearable technologies, and explainable AI are expected to further expand the capabilities of precision oncology while improving diagnostic accuracy, therapeutic effectiveness, and long-term patient outcomes.

Although important scientific, ethical, regulatory, and implementation challenges remain, ongoing collaboration among clinicians, biomedical scientists, engineers, data scientists, and policymakers will accelerate the responsible integration of artificial intelligence into routine oncology practice. The convergence of precision medicine and AI is poised to shape the future of cancer care by delivering more predictive, personalized, and patient-centered healthcare.

References

1. Synthia, F. et al. (2020) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Chaudhary, K. et al. (2021) ‘Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer’, Clinical Cancer Research, 27(5), pp. 1248-1259.
3. Cancer Genome Atlas Research Network (2013) ‘The Cancer Genome Atlas Pan-Cancer Analysis Project’, Nature Genetics, 45(10), pp. 1113-1120.

4. Kather, J.N. et al. (2022) ‘Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations’, Nature Cancer, 3(7), pp. 789-799.
5. Huang, S.C. et al. (2021) ‘Self-supervised Learning for Medical Image Classification: A Systematic Review’, IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
6. Moor, M. et al. (2023) ‘Foundation Models for Generalist Medical Artificial Intelligence’, Nature, 616(7956), pp. 259-265.
7. Wei, L. et al. (2023) ‘Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration’, British Journal of Radiology, 96(1150), Article 20230211.
8. Boehm, K.M. et al. (2022) ‘Harnessing Multimodal Data Integration to Advance Precision Oncology’, Nature Reviews Cancer, 22(2), pp. 114–126.
9. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
10. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
11. Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.
12. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
13. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
14. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38
15. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
16. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
17. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
18. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
19. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31
20. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14

21. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21
22. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
23. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33
24. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.
25. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
26. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
27. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
28. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
29. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
30. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.